This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

PART B - FEE(S) TRANSMITTAL

plete and send this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 (703) 746-4000

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 4 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

or Fax

CURRENT CORRESPONDENCE ADDRESS (Note: Legibly mark-up with any corrections or use Block 1)

25226

11/14/2003

- MORRISON & FOERSTER LLP

-755 PAGE MILL RD

PALO ALTO, CA 94304-1018

Michelle YY. Walker Galileo Pharmaceuticals 5301 Patrick Henry Drive Santa Clara, CA 95054

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission
I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO, on the date indicated below.

(Dopostror's name)	Walker	Michelle Y.
· (Signature)		Mishell
(Date)	, 2004	February 17

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	1
10/020,450	12/14/2001	Guy Michael Miller	346392000900	1698	•

TITLE OF INVENTION: METHODS FOR THE TREATMENT OF NEURONAL DAMAGE ASSOCIATED WITH CEREBRAL ISCHEMIA

APPLN, TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	YES	\$ 665	. \$300	\$965	02/17/2004
EXA	MINER	ART UNIT	CLASS-SUBCLASS	7	
SPIVACK,	PHYLLIS G	1614	514-458000	-	
R 1.363). Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.			names of up to 3 registered patent automoys or agents OR, alternatively, (2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.		

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE; (CITY and STATE OR COUNTRY)

Galileo Pharmaceuticals, Inc.

Santa Clara, California

a individual acorporation or other private group entity agovernment Please check the appropriate assignee category or categories (will not be printed on the patent); 4a. The following fec(s) are enclosed: 4b. Payment of Fee(s): Klasue Fee A check in the amount of the fee(s) is enclosed. Publication Fee ☐ Payment by credit card. Form PTO-2038 is attached. ☐ Advance Order - # of Copies

Director for Patents is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above.

NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office. This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.	(Authorized Signature) Michelle Y.	(Date) Wilker 53,903	2/17/04	80 // 0 /000		
obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Intornation Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patenta, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a		NOTE: The Issue Fee and Publication Fee (if requirement than the applicant a registered attorney or as	red) will not be accepted	d from anyone other party in	01 FC:2501	665.00 DA	3 502247
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.		obtain or retain a benefit by the public which is to a application. Confidentiality is governed by 35 U.S.C. estimated to take 12 minutes to complete, including g completed application form to the USPTO. Time wi case. Any comments on the amount of time you suggestions for reducing this burden, should be sent Parent and Trademark Office, U.S. Department 22313-1450. DO NOT SEND FEES OR COMPLE	file (and by the USPTO 122 and 37 CFR 1.14. The pathering, preparing, and ill vary depending upon require to complete the to the Chlef Information of Commerce, Alexan ETED FORMS TO THI	to process) an anis collection is submitting the the individual is form and/or n Officer, U.S. dria. Virginia	vc rc:1304	300.00 DA	•
		Under the Paperwork Reduction Act of 1995, no collection of information unless it displays a valid OM	persons are required to B control number.	respond to a			

TRANSMIT THIS FORM WITH FEE(S)

PTOL-85 (Rev. 10/03) Approved for use through 04/30/2004.

OMB 0651-0033 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

10020450



Galileo Pharmaceuticals, Inc. 5301 Patrick Henry Drive Santa Clara, CA 95054 gallleopharma.com

Facsimile Transmission

Date: 17 February, 2004

To: USPTO – Mail Stop "ISSUE FEE"

(703) 746-4000

From: Michelle Y. Walker, Patent Agent

408 654 5830x179(voice)

408 654 5831

(fax)

Pages

Please find following "Part B – Fee Transmittal" in duplicate for the issuance of Serial No. 10/020,045.

The information in this facsimile should be treated as confidential and is intended only for the use of the addressee specified above. It should be safeguarded from disclosure to others. If the reader is not the intended recipient, you are hereby notified that retention, verbal disclosure, copyling, or otherwise disseminating this information is strictly forbidden by federal, state and local law. If you receive this fax in error, please notify the sender and return all copies to the address above.